Drugs in Dev. Dermatology
Phase I
Japan 
Lead Product(s) : Nalfurafine
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Immunis
Deal Size : Undisclosed
Deal Type : Partnership
Immunis Partners with Japanese Drug Company Toray to Reverse Sarcopenia
Details : The partnership aims to focus on the clinical development of TRK-820 (nalfurafine hydrochloride), which is being evaluated for the treatment of Uremic Pruritus.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 22, 2024
Lead Product(s) : Nalfurafine
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Immunis
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : ONO-4685
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, Tolerability, PK, PD and Preliminary Efficacy of ONO-4685
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 18, 2022
Lead Product(s) : ONO-4685
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ME3183
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ME3183 is an orally-available and selective inhibitor for phosphodiesterase 4 (PDE4) discovered by Meiji. In the study, ME3183 has been shown to be safe and well-tolerated across the doses tested.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 24, 2021
Lead Product(s) : ME3183
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DS-2741a
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase I Study of DS-2741a in Healthy Volunteers and Participants With Atopic Dermatitis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 26, 2019
Lead Product(s) : DS-2741a
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KHK4323
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of KHK 4323 in Healthy Volunteers and Subjects With Atopic Dermatitis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 19, 2019
Lead Product(s) : KHK4323
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KHK4083
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 1 Study of KHK4083 in Subjects With Atopic Dermatitis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
March 30, 2017
Lead Product(s) : KHK4083
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nalfurafine
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TRK-820 Study in Subjects on Hemodialysis With or Without Uremic Pruritus
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 23, 2016
Lead Product(s) : Nalfurafine
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 14-C SK-1405
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Inapplicable
July 27, 2016
Lead Product(s) : 14-C SK-1405
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SK-1405
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Investigate the Receptor Occupancy of SK-1405 in Healthy, Caucasian, Male Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 08, 2016
Lead Product(s) : SK-1405
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Difamilast
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 1 Trial of OPA-15406 Ointment in Healthy Adult Male Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 08, 2015
Lead Product(s) : Difamilast
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
